AccoladeACCD
ACCD
About: Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.
Employees: 2,400
0
Funds holding %
of 7,363 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
36% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 42
15% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 27
2% more funds holding
Funds holding: 150 [Q3] → 153 (+3) [Q4]
6.71% less ownership
Funds ownership: 83.93% [Q3] → 77.22% (-6.71%) [Q4]
18% less capital invested
Capital invested by funds: $259M [Q3] → $213M (-$45.5M) [Q4]
97% less call options, than puts
Call options by funds: $124K | Put options by funds: $4.8M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
28%
downside
Avg. target
$6.35
9%
downside
High target
$7.03
1%
upside
3 analyst ratings
0 positive
0%
3 neutral
100%
0 negative
0%
Stephens & Co. Jeff Garro 58% 1-year accuracy 7 / 12 met price target | 1%upside $7.03 | Equal-Weight Reiterated | 12 Feb 2025 |
Stifel David Grossman 43% 1-year accuracy 10 / 23 met price target | 1%upside $7.03 | Hold Downgraded | 9 Jan 2025 |
Morgan Stanley Ricky Goldwasser 50% 1-year accuracy 8 / 16 met price target | 28%downside $5 | Equal-Weight Maintained | 17 Dec 2024 |
Financial journalist opinion
Based on 4 articles about ACCD published over the past 30 days
Neutral
PRNewsWire
5 days ago
Accolade Welcomes Oshi Health to Trusted Partner Ecosystem
Partnership increases access to specialized, whole-person clinical care for people managing digestive health conditions SEATTLE , March 6, 2025 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) has partnered with Oshi Health , a leading virtual clinic specializing in gastrointestinal (GI) conditions that delivers convenient, accessible, whole-person care through a collaborative, multidisciplinary approach. This partnership adds to Accolade's existing GI health partnership with Cylinder and reinforces Accolade's commitment to delivering best-in-class health solutions to customers and their employee and member populations.
Positive
Zacks Investment Research
1 week ago
Has Accolade (ACCD) Outpaced Other Business Services Stocks This Year?
Here is how Accolade (ACCD) and Casella (CWST) have performed compared to their sector so far this year.
Neutral
Business Wire
2 weeks ago
ACCD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Accolade, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Accolade, Inc. (NASDAQ: ACCD) to Transcarent for $7.03 per share in cash is fair to Accolade shareholders. Halper Sadeh encourages Accolade shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Accolade and its board.
Neutral
GlobeNewsWire
2 weeks ago
Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction
SAN FRANCISCO and SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, today announced the expiration of the waiting period under the Hart-Scott-Rodino (“HSR”) Antitrust Improvements Act of 1976 with respect to the previously announced merger between the two companies.
Neutral
PRNewsWire
1 month ago
Accolade Expands Virtual Care to Medicare Beneficiaries Nationwide Through PlushCare Direct-to-Consumer Offering
Effort broadens healthcare access and removes barriers to primary care and weight management services SEATTLE , Feb. 4, 2025 /PRNewswire/ -- Today, Accolade, Inc. (NASDAQ: ACCD) announced that its direct-to-consumer virtual healthcare offering, PlushCare, is now accepting Medicare Part B, expanding care access to 64 million beneficiaries across all 50 states. PlushCare offers quality primary care, clinical weight management services, and mental health support from leading providers.
Neutral
PRNewsWire
1 month ago
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Accolade
NEW YORK , Jan. 10, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Accolade (NASDAQ: ACCD) and its board of directors concerning the proposed acquisition of the company by Transcarent. Stockholders will receive $7.03 for each share of Accolade stock that they hold.
Negative
Zacks Investment Research
1 month ago
Accolade (ACCD) Reports Q3 Loss, Lags Revenue Estimates
Accolade (ACCD) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.28 per share a year ago.
Neutral
Business Wire
2 months ago
ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc. - ACCD
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Accolade, Inc. (NasdaqGS: ACCD) to Transcarent. Under the terms of the proposed transaction, shareholders of Accolade will receive $7.03 in cash for each share of Accolade that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the considera.
Positive
Benzinga
2 months ago
Why Is Accolade Stock Trading Over 100% On Tuesday?
Transcarent agreed to buy Accolade Inc ACCD Wednesday for $621 million.
Neutral
Business Wire
2 months ago
Shareholder Alert: Ademi LLP Investigates Whether Accolade, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Accolade (NASDAQ: ACCD) for possible breaches of fiduciary duty and other violations of law in its transaction with the Transcarent. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Accolade stockholders will receive $7.03 per share in cash, which represents a total equity value of ap.
Charts implemented using Lightweight Charts™